Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152030369> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2152030369 abstract "Objective: To report the first case of myoclonus as neurologic presentation of 5-MeO-DALT abuseBackground: 5-Meo-DALT (N,N-diallyl-5-methoxytryptamine) is a relatively new hallucinogen, initially sold online in 2004. It is a psychedelic compound from the tryptamine family which affects monoamine neurotransmitters including dopamine and serotonin. It is a psychostimulant with strong visual hallucinogenic and entheogenic effects. It can be smoked, taken orally or sniffed. It is not detected in routine toxicology screen. Typical symptoms include extreme agitation, tachycardia, and combativeness. Little is known about neurologic symptoms. Delirium was reported in one case, but myoclonus or other movement disorders have never been reported.Methods: A case reportResults/Case: A 29-year old-man was admitted for markedly reduced oral intake for four days. He became unresponsive on the next day in hospital, and developed intermittent myoclonus. He had history of heroin and marijuana abuse, and was on buprenorphine. Myoclonic jerks involved all extremities, trunk, and neck with possible spread to lower jaw. The movements coalesced and recurred in cyclic pattern, approximately every 10 minutes (see Video). Somesthetic stimuli aggravated the jerks. Electrophysiologic testing was not available, but clinical examination suggested a brainstem or high spinal origin. After a dose of intravenous lorazepam, he partially regained consciousness, and myoclonus stopped, but the effects were transient. Urine toxicology screen was positive for opioid and cannabinoid. Electroencephalography did not reveal ictal or interictal epileptiform discharges. MRI brain was unremarkable. Myoclonus and encephalopathy gradually improved over a week. Once he returned back to his baseline, he reported 5-Meo-DALT use prior to this admission, and prior visual hallucinations and delusions.Conclusions: This substance abuse should be considered in patients with cyclic myoclonus and negative toxicology screen. Further studies are helpful in expanding the knowledge on neurologic features of 5-Meo-DALT abuse, and development of the screening to cover this substance. Disclosure: Dr. Thammongkolchai has nothing to disclose. Dr. Termsarasab has nothing to disclose. Dr. Alkhachroum has nothing to disclose. Dr. Gujrati has nothing to disclose. Dr. Frucht has received personal compensation for activities with Merz Pharmaceuticals as a consultant. Dr. Katirji has nothing to disclose." @default.
- W2152030369 created "2016-06-24" @default.
- W2152030369 creator A5044264487 @default.
- W2152030369 creator A5047790773 @default.
- W2152030369 creator A5051099410 @default.
- W2152030369 creator A5051707876 @default.
- W2152030369 creator A5075135174 @default.
- W2152030369 creator A5085908951 @default.
- W2152030369 date "2015-04-06" @default.
- W2152030369 modified "2023-09-24" @default.
- W2152030369 title "5-Meo-DALT-induced Cyclic Myoclonus (P3.013)" @default.
- W2152030369 hasPublicationYear "2015" @default.
- W2152030369 type Work @default.
- W2152030369 sameAs 2152030369 @default.
- W2152030369 citedByCount "0" @default.
- W2152030369 crossrefType "journal-article" @default.
- W2152030369 hasAuthorship W2152030369A5044264487 @default.
- W2152030369 hasAuthorship W2152030369A5047790773 @default.
- W2152030369 hasAuthorship W2152030369A5051099410 @default.
- W2152030369 hasAuthorship W2152030369A5051707876 @default.
- W2152030369 hasAuthorship W2152030369A5075135174 @default.
- W2152030369 hasAuthorship W2152030369A5085908951 @default.
- W2152030369 hasConcept C118552586 @default.
- W2152030369 hasConcept C15744967 @default.
- W2152030369 hasConcept C2776538686 @default.
- W2152030369 hasConcept C2777257487 @default.
- W2152030369 hasConcept C2778621155 @default.
- W2152030369 hasConcept C2910982124 @default.
- W2152030369 hasConcept C42219234 @default.
- W2152030369 hasConcept C71924100 @default.
- W2152030369 hasConceptScore W2152030369C118552586 @default.
- W2152030369 hasConceptScore W2152030369C15744967 @default.
- W2152030369 hasConceptScore W2152030369C2776538686 @default.
- W2152030369 hasConceptScore W2152030369C2777257487 @default.
- W2152030369 hasConceptScore W2152030369C2778621155 @default.
- W2152030369 hasConceptScore W2152030369C2910982124 @default.
- W2152030369 hasConceptScore W2152030369C42219234 @default.
- W2152030369 hasConceptScore W2152030369C71924100 @default.
- W2152030369 hasLocation W21520303691 @default.
- W2152030369 hasOpenAccess W2152030369 @default.
- W2152030369 hasPrimaryLocation W21520303691 @default.
- W2152030369 hasRelatedWork W1429726707 @default.
- W2152030369 hasRelatedWork W1488971793 @default.
- W2152030369 hasRelatedWork W1599637743 @default.
- W2152030369 hasRelatedWork W1971288427 @default.
- W2152030369 hasRelatedWork W1999687457 @default.
- W2152030369 hasRelatedWork W2008372595 @default.
- W2152030369 hasRelatedWork W2072178780 @default.
- W2152030369 hasRelatedWork W2072552780 @default.
- W2152030369 hasRelatedWork W2102245578 @default.
- W2152030369 hasRelatedWork W2123554163 @default.
- W2152030369 hasRelatedWork W2150931123 @default.
- W2152030369 hasRelatedWork W2163812512 @default.
- W2152030369 hasRelatedWork W2337076360 @default.
- W2152030369 hasRelatedWork W2792179464 @default.
- W2152030369 hasRelatedWork W2884544823 @default.
- W2152030369 hasRelatedWork W2912912132 @default.
- W2152030369 hasRelatedWork W3083969149 @default.
- W2152030369 hasRelatedWork W3169393671 @default.
- W2152030369 hasRelatedWork W3184837910 @default.
- W2152030369 hasRelatedWork W3200776291 @default.
- W2152030369 hasVolume "84" @default.
- W2152030369 isParatext "false" @default.
- W2152030369 isRetracted "false" @default.
- W2152030369 magId "2152030369" @default.
- W2152030369 workType "article" @default.